Hisashi Uhara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hisashi Uhara has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Toshiaki Saida
Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan
15 shared publications - Ryuhei Okuyama
Department of Dermatology Shinshu University School of Medicine Matsumoto Japan
13 shared publications Ryuhei Okuyama
Department of Dermatology, Shinshu University School of Medicine, Nagano, Japan
7 shared publicationsToshiaki Saida
Department of Dermatology, Shinshu University School of Medicine, Asahi, Matsumoto
5 shared publicationsMinoru Takata
Department of Dermatology, Shinshu University School of Medicine, Asahi, Matsumoto
4 shared publicationsYasutomo Mikoshiba
Department of Dermatology, Shinshu University School of Medicine, Matsumoto
4 shared publications
Latest Publications
- Open Access
- 1 December 2016
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 8 (3) , 341-343
Late Onset of Acute Urticaria after Bee Stings
Here we report the cases of five patients with a late onset of acute urticaria after a bee sting. The ages of the five Japanese patients ranged from 33 to 86 years (median: 61). All patients had no history of an allergic reaction to bee stings. The onset of urticaria was 6–14 days (median: 10) after a bee sting. Although four of the patients did not describe experiencing a bee sting at their presentation, the subsequent examination detected anti-bee-specific IgE antibodies. So, we think a history of a bee sting should thus be part of the medical interview sheet for patients with acute urticaria, and an examination of IgE for bees may help prevent a severe bee-related anaphylactic reaction in the future.
- 1 December 2016
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 8 (3) , 341-343
Open AccessLate Onset of Acute Urticaria after Bee Stings
Here we report the cases of five patients with a late onset of acute urticaria after a bee sting. The ages of the five Japanese patients ranged from 33 to 86 years (median: 61). All patients had no history of an allergic reaction to bee stings. The onset of urticaria was 6–14 days (median: 10) after a bee sting. Although four of the patients did not describe experiencing a bee sting at their presentation, the subsequent examination detected anti-bee-specific IgE antibodies. So, we think a history of a bee sting should thus be part of the medical interview sheet for patients with acute urticaria, and an examination of IgE for bees may help prevent a severe bee-related anaphylactic reaction in the future.
- 5 October 2016
- Published by Wiley in The Journal of Dermatology
- Vol. 43 (10) , 1247-1248
Orange pigmentation spots on the sole may be from a stink bug
- 5 October 2016
- Published by Wiley in The Journal of Dermatology
- Vol. 43 (10) , 1247-1248
Orange pigmentation spots on the sole may be from a stink bug
- 1 October 2016
- Published by Elsevier in Journal of Dermatological Science
- Vol. 84 (1) , e85
Activation of Toll-like receptor 4 induces proliferation and migration of human melanoma cells
- 1 October 2016
- Published by Elsevier in Journal of Dermatological Science
- Vol. 84 (1) , e85
Activation of Toll-like receptor 4 induces proliferation and migration of human melanoma cells
- 12 January 2016
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 46 (3) , 270-272
Nivolumab-induced organizing pneumonia in a melanoma patient
We report the case of a 70-year-old woman with vaginal melanoma and multiple metastases in the lung. After the third dose of nivolumab, decreased room-air resting arterial oxygen saturation with bilateral basal fine crackles on auscultation developed despite the absence of respiratory symptoms. Computed tomography showed ground-glass opacities with airspace consolidations scattered with a peculiar distribution, and most were observed around the existing metastatic tumors in the lung. From the 42nd day to the 56th day after the last administration of nivolumab, she received dexamethasone 1–2 mg/body for the prevention of adverse events after stereotactic radiation for brain metastasis. At 3 months after the last administration of nivolumab, a computed tomography scan revealed improvement of the pneumonia and a decreased size and number of metastatic lesions in the lung, although some lesions showed enlargement. Further examination is needed to clarify the relationship between the pattern of pneumonia after Nivo therapy and clinical effects.
- 12 January 2016
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 46 (3) , 270-272
Nivolumab-induced organizing pneumonia in a melanoma patient
We report the case of a 70-year-old woman with vaginal melanoma and multiple metastases in the lung. After the third dose of nivolumab, decreased room-air resting arterial oxygen saturation with bilateral basal fine crackles on auscultation developed despite the absence of respiratory symptoms. Computed tomography showed ground-glass opacities with airspace consolidations scattered with a peculiar distribution, and most were observed around the existing metastatic tumors in the lung. From the 42nd day to the 56th day after the last administration of nivolumab, she received dexamethasone 1–2 mg/body for the prevention of adverse events after stereotactic radiation for brain metastasis. At 3 months after the last administration of nivolumab, a computed tomography scan revealed improvement of the pneumonia and a decreased size and number of metastatic lesions in the lung, although some lesions showed enlargement. Further examination is needed to clarify the relationship between the pattern of pneumonia after Nivo therapy and clinical effects.
- Open Access
- 21 October 2015
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 46 (1) , 86-88
Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma
We reported an 81-year-old woman with metastatic melanoma, in whom myasthenia gravis and rhabdomyolysis developed after nivolumab monotherapy. The first symptom of myasthenia gravis was dyspnea. Ultrasonography detected hypokinesis of the bilateral diaphragm suggesting myasthenia gravis, although there was no abnormal finding of the lungs in computed tomography images. Acetylcholine receptor binding antibodies were low-titer positive in the preserved serum before administration of nivolumab, strongly suggesting that the myasthenia gravis was a nivolumab-related immune adverse event. Despite the remarkable clinical benefits of immune checkpoint inhibitors for patients with advanced melanoma, it is important to recognize unexpected immune-related adverse events.
- 21 October 2015
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 46 (1) , 86-88
Open AccessAcetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma
We reported an 81-year-old woman with metastatic melanoma, in whom myasthenia gravis and rhabdomyolysis developed after nivolumab monotherapy. The first symptom of myasthenia gravis was dyspnea. Ultrasonography detected hypokinesis of the bilateral diaphragm suggesting myasthenia gravis, although there was no abnormal finding of the lungs in computed tomography images. Acetylcholine receptor binding antibodies were low-titer positive in the preserved serum before administration of nivolumab, strongly suggesting that the myasthenia gravis was a nivolumab-related immune adverse event. Despite the remarkable clinical benefits of immune checkpoint inhibitors for patients with advanced melanoma, it is important to recognize unexpected immune-related adverse events.
- 1 October 2015
- Published by Elsevier in Journal of Dermatological Science
- Vol. 80 (1) , 33-37
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients
- 1 October 2015
- Published by Elsevier in Journal of Dermatological Science
- Vol. 80 (1) , 33-37
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients
- 27 July 2015
- Published by Wiley in The Journal of Dermatology
- Vol. 42 (11) , 1121-1122
Primary cutaneous nocardiosis caused by Nocardia concava
- 27 July 2015
- Published by Wiley in The Journal of Dermatology
- Vol. 42 (11) , 1121-1122
Primary cutaneous nocardiosis caused by Nocardia concava
- 2 April 2014
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 20 (1) , 194-197
Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget’s disease
Extramammary Paget’s disease (EPD) is a cutaneous adenocarcinoma. It is usually curable by wide local excision. However, the prognosis for EPD patients with metastases is extremely poor because effective chemotherapy for advanced EPD has not been established. We retrospectively analyzed the efficacy of combination chemotherapy consisting of infusions of 5-fluorouracil (5-FU, 600 mg/m2/body, 5 days/week) and cisplatin (5–10 mg/body, 5–7 days/week) administered intravenously for 8–24 h (low-dose FP). The patients were 15 males and 7 females and the ages ranged from 54 to 91 years old (median 71). The toxicities of low-dose FP were as follows: hematopoietic dysfunction (n = 4), gastrointestinal dysfunction (4), nephropathy (1), and phlebitis (1). Almost all toxicities were grade 1 or 2 except for 2 cases with grade 3 leukopenia or pancytopenia. Seventeen patients were treated with low-dose FP only, and the clinical results included 10 partial responses (PR), 4 stable disease (SD), and 3 progressive disease (PD). The overall survival ranges (medians) were 5–51 months (12) in all 22 patients, 6–51 months (13) in the 13 patients showing complete response or PR, and 5–12 months (11) in the 6 SD patients. The reported palliative effects of low-dose FP include control of pain and improvement of lymphedema. Although the number of cases is limited and there is a bias because cases without clinical effects are less likely to be reported, this regimen might be considered a relatively effective option for advanced EPD.
- 2 April 2014
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 20 (1) , 194-197
Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget’s disease
Extramammary Paget’s disease (EPD) is a cutaneous adenocarcinoma. It is usually curable by wide local excision. However, the prognosis for EPD patients with metastases is extremely poor because effective chemotherapy for advanced EPD has not been established. We retrospectively analyzed the efficacy of combination chemotherapy consisting of infusions of 5-fluorouracil (5-FU, 600 mg/m2/body, 5 days/week) and cisplatin (5–10 mg/body, 5–7 days/week) administered intravenously for 8–24 h (low-dose FP). The patients were 15 males and 7 females and the ages ranged from 54 to 91 years old (median 71). The toxicities of low-dose FP were as follows: hematopoietic dysfunction (n = 4), gastrointestinal dysfunction (4), nephropathy (1), and phlebitis (1). Almost all toxicities were grade 1 or 2 except for 2 cases with grade 3 leukopenia or pancytopenia. Seventeen patients were treated with low-dose FP only, and the clinical results included 10 partial responses (PR), 4 stable disease (SD), and 3 progressive disease (PD). The overall survival ranges (medians) were 5–51 months (12) in all 22 patients, 6–51 months (13) in the 13 patients showing complete response or PR, and 5–12 months (11) in the 6 SD patients. The reported palliative effects of low-dose FP include control of pain and improvement of lymphedema. Although the number of cases is limited and there is a bias because cases without clinical effects are less likely to be reported, this regimen might be considered a relatively effective option for advanced EPD.
- 29 January 2014
- Published by Wiley in The Journal of Dermatology
- Vol. 41 (2) , 192-193
Marked histiocytic infiltration in neonatal lupus erythematosus
- 29 January 2014
- Published by Wiley in The Journal of Dermatology
- Vol. 41 (2) , 192-193
Marked histiocytic infiltration in neonatal lupus erythematosus